The new consortium partners expand CSDR's ability to help accelerate life-saving discoveries and efficiently translate big data into smart data that generates valuable research results.
With the addition of non-profit partners, CSDR is uniquely positioned to not only serve the research community through access to patient-level clinical data from the pharmaceutical industry, but also as a resource through which academic-led clinical trial data now can be shared.
ClinicalStudyDataRequest.com is an online resource giving researchers access to patient-level clinical trial data from 14 pharmaceutical companies across multiple therapeutic areas.
Its multi-sponsor request system provides a secure process for researchers to request access to global clinical trial data through a publicly available website.
An independent review panel reviews data requests received from external researchers. Wellcome Trust provides secretarial support to this panel and oversees the review process.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA